Cargando…

Progress toward Better Treatment of Therapy-Related AML

SIMPLE SUMMARY: Therapy-related acute myeloid leukemia (t-AML) is one of the most serious long-term complications of cancer chemotherapy. Various cytotoxic agents and exposure to ionizing radiation can lead to the development of t-AML, which is usually associated with adverse genetic changes and a p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotsiafti, Angeliki, Giannakas, Konstantinos, Christoforou, Panagiotis, Liapis, Konstantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10046015/ https://www.ncbi.nlm.nih.gov/pubmed/36980546 http://dx.doi.org/10.3390/cancers15061658

Ejemplares similares

Towards a Better Understanding of Cohesin Mutations in AML
por: Cuartero, Sergi, et al.
Publicado: (2019)

Anatomic variations of the Uterine Artery. Review of the literature and their clinical significance
por: Liapis, Konstantinos, et al.
Publicado: (2020)

Precision medicine in the treatment stratification of AML patients: challenges and progress
por: Lohse, Ines, et al.
Publicado: (2018)

Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches
por: Winer, Eric S., et al.
Publicado: (2019)

Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?
por: Liapis, Konstantinos, et al.
Publicado: (2021)

The Economics of a “portion size reduction” policy
por: Hosni, Hanin, et al.
Publicado: (2022)

Causes and consequences of fake transparency/excess information in food claims
por: Ray, Susweta, et al.
Publicado: (2022)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

Rapidly Progressive Pauci-Immune Glomerulonephritis with Aberrant Fibrinoid Necrosis Associated with Atezolizumab, an Immune Check Point Inhibitor: A Case Report and Review of Literature
por: Nikolopoulos, Petros, et al.
Publicado: (2023)

The Relation between Caffeine Consumption and Endometriosis: An Updated Systematic Review and Meta-Analysis
por: Kechagias, Konstantinos S., et al.
Publicado: (2021)

Who Has Therapy-Related AML?
por: Gale, Robert Peter, et al.
Publicado: (2017)

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)
por: Assouline, Sarit, et al.
Publicado: (2012)

Clustering and disease subtyping in Neuroscience, toward better methodological adaptations
por: Poulakis, Konstantinos, et al.
Publicado: (2023)

AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances
por: Koenig, Kristin L., et al.
Publicado: (2020)

Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review
por: Grigoropoulos, Ioannis, et al.
Publicado: (2019)

The role of premium subsidies in crop insurance
por: Mavroutsikos, Charalampos, et al.
Publicado: (2021)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

The Black Hole: CAR T Cell Therapy in AML
por: Atilla, Erden, et al.
Publicado: (2023)

The blind men and the AML elephant: can we feel the progress?
por: Tauro, S
Publicado: (2016)

Autophagy a Close Relative of AML Biology
por: Joffre, Carine, et al.
Publicado: (2021)

Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
por: Engen, Caroline Benedicte Nitter, et al.
Publicado: (2014)

Evaluating ivosidenib for the treatment of relapsed/refractory AML: design, development, and place in therapy
por: Nassereddine, Samah, et al.
Publicado: (2018)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

Biomarkers as targets for CAR-T/NK cell therapy in AML
por: Shao, Ruonan, et al.
Publicado: (2023)

Clinical Results of Hypomethylating Agents in AML Treatment
por: Cruijsen, Marjan, et al.
Publicado: (2014)

Emerging CAR T Cell Strategies for the Treatment of AML
por: Vishwasrao, Paresh, et al.
Publicado: (2022)

Increasing Role of Targeted Immunotherapies in the Treatment of AML
por: Greiner, Jochen, et al.
Publicado: (2022)

Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
por: Marofi, Faroogh, et al.
Publicado: (2021)

Recent Advances in the Development of Anti-FLT3 CAR T-Cell Therapies for Treatment of AML
por: Pedersen, Maya Graham, et al.
Publicado: (2022)

Combination Therapies Targeting Apoptosis in Paediatric AML: Understanding the Molecular Mechanisms of AML Treatments Using Phosphoproteomics
por: Ali, Ahlam A., et al.
Publicado: (2023)

Reconstructing semileptonic top-pairs using different strategies
por: Christoforou, Konstantinos
Publicado: (2018)

The Time Has Come for Targeted Therapies for AML: Lights and Shadows
por: Fiorentini, Alessandro, et al.
Publicado: (2020)

Irene Higginson: progress towards a better ending
por: Watts, Geoff
Publicado: (2020)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Treatment of scalene muscles with the Ergon technique can lead to greater improvement in hip abduction range of motion than local hip adductor treatment: a study on deep front line connectivity
por: Kazakos, Dimitrios, et al.
Publicado: (2020)

Diagnosis and Treatment of Patients With Acute Myeloid Leukemia With Myelodysplasia-Related Changes (AML-MRC)
por: Arber, Daniel A, et al.
Publicado: (2020)

Towards Better Delivery of Cannabidiol (CBD)
por: Millar, Sophie Anne, et al.
Publicado: (2020)

Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment.
por: Pachner, A. R.
Publicado: (1987)

Sex-Related Effects on Cardiac Development and Disease
por: Siokatas, Georgios, et al.
Publicado: (2022)

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
por: Chen, Jing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_thmqu7t5g7bc3hpqlpnqepfc3l